The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.


Saydam G., Ali R., Demir A. M., Eskazan A. E., Guvenc B., Haznedaroglu I. C., ...Daha Fazla

International journal of hematologic oncology, cilt.11, sa.1, 2022 (Hakemli Dergi) identifier